Status:

COMPLETED

Immune Indicators of Uveitis

Lead Sponsor:

National Eye Institute (NEI)

Conditions:

GITR

GITR Ligand

Eligibility:

All Genders

18+ years

Brief Summary

This study will try to identify markers of immune activity in uveitis patients that correlate with the state of disease activity. Uveitis is a group of inflammatory eye diseases that can cause vision ...

Detailed Description

Indicators of disease activity in supposed autoimmune conditions are actively being sought. We have already described the increased expression of GITR-glucocorticoid induced TNF-related family recepto...

Eligibility Criteria

Inclusion

  • INCLUSION CRITERIA:
  • Patients with bilateral sight threatening uveitis requiring systemic immunotherapy who are 18 years and older are eligible. Disease can be active or quiescent, but subjects must be on a minimum prescribed therapy upon enrollment of a dose averaging at least 20 mg/day (or greater than or equal to 0.25 mg/kg/day) of systemic prednisone or a more intensive immunosuppression regimen. More intensive regimens may include from one to three anti-inflammatory treatments for uveitis that include any one of the following (or related) compounds: corticosteroids (including systemic or periorbital administration), topical corticosteroids (when used in combination with other agents), cyclophosphamide, cyclosporine, azathioprine, chlorambucil, tacrolimus, leflunomide, mycophenolate mofetil, or methotrexate.
  • Patients who have non-infectious intermediate, posterior, or panuveitis of at least 3 months duration. Included conditions may include but are not limited to intermediate uveitis of the pars planitis subtype, sarcoidosis, the Vogt-Koyanagi-Harada (VKH) syndrome, birdshot retinochoroidopathy, retinal vasculitis and sympathetic ophthalmia.
  • Patients who are 18 years of age or older.
  • EXCLUSION CRITERIA:
  • Subjects will not be able to enroll if they:
  • Are unwilling or unable to give blood at the designated times in the protocol.
  • Have another disease or condition affecting vision that will interfere with obtaining study data
  • Are pregnant

Exclusion

    Key Trial Info

    Start Date :

    August 9 2004

    Trial Type :

    OBSERVATIONAL

    End Date :

    October 28 2008

    Estimated Enrollment :

    100 Patients enrolled

    Trial Details

    Trial ID

    NCT00089739

    Start Date

    August 9 2004

    End Date

    October 28 2008

    Last Update

    July 2 2017

    Active Locations (1)

    Enter a location and click search to find clinical trials sorted by distance.

    Page 1 of 1 (1 locations)

    1

    National Institutes of Health Clinical Center, 9000 Rockville Pike

    Bethesda, Maryland, United States, 20892